Drugs / BEFIRADOL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05148884 | Nov 2021 → Jan 2023 | drug-induced dyskinesia | Neurolixis SAS | Completed | Met primary |
News releases announcing trial results or a regulatory action · 15
| Date | Issuer | Release |
|---|---|---|
| 2025-03-18 | Neurolixis SAS | Results 18 March 2025 - Neurolixis Publishes Positive Phase 2A Trial Results for NLX-112 in Parkinson’s Disease neurolixis.com ↗
Neurolixis today announced the publication of the results from its successful Phase 2A proof-of-concept clinical trial of NLX-112 (befiradol) in Parkinson’s disease. |
| 2024-09-25 | Neurolixis SAS | Regulatory 25 September 2024 - Neurolixis granted Orphan Medicinal Product Designation for NLX-112 as a Treatment for Spinocerebellar Ataxia neurolixis.com ↗
NLX-112 , a highly selective serotonin 5-HT1A receptor agonist, has been granted Orphan Medicinal Product (OMP) Designation by the European Commission for the treatment of Spinocerebellar Ataxia (SCA; approval #EU/3/24/2951). |
| 2024-01-15 | Neurolixis SAS | Results 15 January 2024 - Successful NLX-112 clinical results discussed in interview with Parkinson's UK foundation neurolixis.com ↗
NLX-112 is a first-in-kind non-dopaminergic drug for treatment of dyskinesia and other symptoms of Parkinson's disease and exhibited positive effects against dyskinesia and parkinsonism in a recent study supported by The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK research foundations. |
| 2023-08-25 | Neurolixis SAS | Results 25 August 2023 - Dual Clinical Efficacy of NLX-112 in Parkinson's Disease to be Presented at Movement Disorders Society Congress neurolixis.com ↗
NLX-112 , a ground-breaking, non-dopaminergic drug, exhibited both anti-dyskinetic and anti-parkinsonian properties in a proof-of-concept Phase 2A clinical trial. |
| 2023-03-20 | Neurolixis SAS | Results 20 March 2023 - Neurolixis Announces Positive Ph2A Proof-of-Concept on NLX-112 in Levodopa-Induced Dyskinesia in Parkinson’s Disease neurolixis.com ↗
Neurolixis, Inc. today announced the positive results of its Phase 2A clinical trial with NLX-112 (befiradol), for treatment of levodopa-induced dyskinesias (LID) in Parkinson’s disease (PD). |
| 2021-02-15 | Neurolixis SAS | Results 15 February 2021 - NLX-112 Restores Motor Function in a Transgenic Model of Spinocerebellar Ataxia neurolixis.com ↗
NLX-112 , a serotonin 5-HT 1A receptor agonist developed by Neurolixis, reversed motor deficits in a transgenic model of Spinocerebellar ataxia3 (SCA3), a rare genetic orphan disease. |
| 2020-08-24 | Neurolixis SAS | Results 24 August 2020 - Antidyskinetic activity of NLX-112 in an additional non-human primate species neurolixis.com ↗
When the macaques received NLX-112, their dyskinesia symptoms were strongly reduced, confirming a previous study carried out in parkinsonian marmosets. |
| 2020-03-02 | Neurolixis SAS | Results 2 March 2020 - NLX-112 shows antidyskinetic and antiparkinsonian activity in non-human primate study neurolixis.com ↗
The results showed that NLX-112 successfully reduced dyskinesia and, crucially, did not significantly reduce the effectiveness of L-DOPA, which many other similar drugs do. |
| 2019-08-20 | Neurolixis SAS | Results 20 August 2019 - First human brain imaging of serotonin 5-HT1A receptors using 18F-NLX-112 as agonist PET tracer neurolixis.com ↗
The study shows that, unlike previous radiotracers, 18F-labeled NLX-112 binds to 5-HT1A receptors which are functionally-responsive, and shows accentuated labeling in specific cortical brain regions. |
| 2019-03-12 | Neurolixis SAS | Regulatory 12 March 2019 - FDA approves Neurolixis IND application for clinical trial with NLX-112 neurolixis.com ↗ |
| 2018-07-25 | Neurolixis SAS | Results 25 July 2018 - Just Published: PET and fMRI imaging on NLX-112 and NLX-101 neurolixis.com ↗ |
| 2017-08-07 | Neurolixis SAS | Results 7 August 2017 - Just Published: article on NLX-112 analgesic activity in mouse neurolixis.com ↗
It exhibited potent analgesic activity in the mouse formalin test, a model of tonic pain, possibly through activation of spinal cord serotonin 5-HT1A receptors. |
| 2017-06-14 | Neurolixis SAS | Results 14 June 2017 - Just Published: article on NLX-112 agonist properties in vitro neurolixis.com ↗
NLX-112 was tested in a variety of in vitro assays of serotonin 5-HT1A receptor activation and consistently exhibited very high agonist efficacy. |
| 2016-02-22 | Neurolixis SAS | Results 22 February 2016 - Just Published: articles on NLX-112 in models of dyskinesia in Parkinson's disease neurolixis.com ↗ |
| 2015-06-04 | Neurolixis SAS | Regulatory 04 June 2015 - Neurolixis SAS awarded French 'Young Innovative Company' status neurolixis.com ↗
Neurolixis SAS , the French subsidiary of Neurolixis Inc. based in Castres , near Toulouse, announced today that it had been awarded 'Jeune Entreprise Innovante' (JEI; literally 'Young Innovative Company') status by the French Public Finances Directorate. |
All press releases naming this drug 23 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEFIRADOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL45305 ↗ |
| Known as | F-13640 | ChEMBL registry synonym — accepted as the source's own label CHEMBL45305 ↗ |
| Known as | NLX-112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05148884 ↗ |
| Action | Activate | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL45305 ↗1“5-HT1A receptor agonist” NCT05148884 ↗ |
| Modality | Small molecule | — CHEMBL45305 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL45305 ↗ |